Medical Condition News

RSS

New research provides explanation for some of autism's mysteries

New research from Carnegie Mellon University's Marcel Just provides an explanation for some of autism's mysteries - from social and communication disorders to restricted interests - and gives scientists clear targets for developing intervention and treatment therapies.

7 Mar 2012

NeuroVista technology shows promise in detecting and predicting seizures

Mayo Clinic and partners from the University of Pennsylvania School of Veterinary Medicine, the University of Minnesota College of Veterinary Medicine and College of Pharmacy, the Perelman School of Medicine at the University of Pennsylvania, and NeuroVista Corporation have been awarded $7.5 million grant (U01) from the National Institute of Neurological Disorders and Stroke, a division of the National Institutes of Health.

7 Mar 2012

Vitamin D deficiency may increase risk of mortality in institutionalized elderly patients

The majority of institutionalized elderly female patients are vitamin D deficient and there is an inverse association of vitamin D deficiency and mortality, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology and Metabolism.

7 Mar 2012

A&G, Mayo Medical sign license agreement for new progranulin blood test for FTD

Mayo Clinic today announced that Mayo Medical Laboratories has signed an agreement with A&G Pharmaceutical, Inc. and will receive a non-exclusive license to certain patent rights and proprietary antibody reagents for the detection and measurement of progranulin in blood.

7 Mar 2012

Nitrogen balance occurs with a precise 24-hour rhythm in mammals

Researchers at Case Western Reserve University School of Medicine demonstrated that nitrogen balance, the process of utilizing amino acids and disposing of their toxic byproducts, occurs with a precise 24-hour rhythm - also known as circadian rhythm - in mammals. Disruption of this cycle has a direct impact on survival of organisms, and may predispose one to life altering diseases including diabetes and cardiovascular disease.

7 Mar 2012

Many patients with rare forgotten cancers pay a high price

Thousands of patients with rare "forgotten cancers" are paying a high price because doctors lack awareness of their conditions, according to a speaker at the 4th ESMO Conference on Sarcoma and GIST.

7 Mar 2012

Yoga may be effective in treating patients with stress-related psychological and medical conditions

An article by researchers from Boston University School of Medicine (BUSM), New York Medical College (NYMC), and the Columbia College of Physicians and Surgeons (CCPS) reviews evidence that yoga may be effective in treating patients with stress-related psychological and medical conditions such as depression, anxiety, high blood pressure and cardiac disease.

7 Mar 2012

Pten gene can also fight against obesity, ageing process

This result, obtained after five years' research, is published in leading journal Cell Metabolism. The authors, led by Manuel Serrano (CNIO), believe it will open the door to new therapeutic options not only against cancer, but against obesity and even the ageing process.

7 Mar 2012

Scientists develop nanocombinatorics for directing stem cell differentiation

Northwestern University scientists have developed a powerful analytical method that they have used to direct stem cell differentiation. Out of millions of possibilities, they rapidly identified the chemical and physical structures that can cue stem cells to become osteocytes, cells found in mature bone.

7 Mar 2012

First study to demonstrate cost-effectiveness of intensive TBI care

Aggressive treatment for severe traumatic brain injuries costs more than routine care, yet yields significantly better outcomes, improved quality of life, and lower long term care costs, according to a new study by researchers in the Perelman School of Medicine at the University of Pennsylvania.

7 Mar 2012

Timely treatment with Berinert provides faster symptom relief for HAE patients

CSL Behring announced today that treatment with Berinert, C1 Esterase Inhibitor (Human) within six hours of the onset of an acute hereditary angioedema (HAE) attack provides faster symptom relief than later treatment, according to data presented at the 2012 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

7 Mar 2012

Researchers reveal how melanoma develops resistance to Zelboraf

Cancer is tough to kill and has many ways of evading the drugs used by oncologists to try and eliminate it. Now, researchers at UCLA's Jonsson Comprehensive Cancer Center have uncovered how an advanced form of melanoma gets around an inhibitor, Zelboraf, which targets the mutated BRAF gene.

7 Mar 2012

Shire to commence two Vyvanse and Concerta Phase 4 comparison trials for ADHD

As part of its continued commitment to ADHD research, Shire plc, the global specialty biopharmaceutical company, today announced it is initiating two Phase 4 clinical trials to compare Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) to Concerta (methylphenidate HCl) Extended-Release Tablets.

7 Mar 2012

People with schizophrenia benefit from new evidence-based clinical program

People with schizophrenia report improved functioning after participating in a new, evidence-based clinical program, according to results announced today from a six-month pilot.

7 Mar 2012

Tree nut consumption may reduce weight and health risks

March is National Nutrition Month and as the spotlight shines on all things healthy, celebrate with a mindful snack that loves you back-California pistachios.

7 Mar 2012

CU Cancer Center aims to make progress against squamous cell lung cancer

Recent advances in targeted cancer treatments greatly bolster the prognosis for many types of lung cancer, but according to a University of Colorado Cancer Center investigator, "practically nothing has improved in squamous cell lung cancer in the last decades."

7 Mar 2012

FDA issues Complete Response Letter to Eisai for Dacogen sNDA

Astex Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter to partner Eisai for their supplemental New Drug Application (sNDA) for Dacogen (decitabine) for Injection for patients with acute myeloid leukemia (AML) in adults 65 years of age or older who are not considered candidates for induction therapy.

7 Mar 2012

Altogen launches new pancreas-targeted in vivo RNAi transfection system

Altogen Biosystems announced the launch of its new pancreas-targeted in vivo RNAi transfection system in the company's popular in vivo delivery product line for use in laboratories and research facilities for development of new medicines and testing in cells and animals.

7 Mar 2012

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the company's ANTISENILIN monoclonal antibody platform technology for the treatment and prevention of Alzheimer's disease.

7 Mar 2012

Bevacizumab drug improves cardiac output in patients with HHT

In a small study that included 25 patients with hereditary hemorrhagic telangiectasia (a genetic disorder that leads to abnormalities of blood vessels) and severe liver involvement with this disease, patients who received the drug bevacizumab had improved cardiac output and a reduction in the duration and number of episodes of nose bleeds, a potentially life-threatening complication for patients with this disorder, according to a study in the March 7 issue of JAMA.

6 Mar 2012